WASHINGTON/NEW YORK (Reuters) - The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate "inversions," with the pending $160 billion merger of Pfizer Inc and Allergan Plc ...

Less than 24 hours after the Obama administration escalated its battle against corporate tax inversions, the outcome of at least one major pending U.S. merger seemed clouded by doubt Tuesday. The ...

The White House said Wednesday that the Treasury Department’s new rules aimed at curbing corporate inversions were not specifically targeted at the prospective Pfizer and Allergen merger that the ...

Pharmaceutical giants Pfizer and Allergan were forced to abandon their $160 billion merger in April following the US Treasury’s clampdown on tax inversion deals. This would have been the largest ...